KEGG   DRUG: AtezolizumabHelp
Entry
D10773                      Drug                                   

Name
Atezolizumab (USAN/INN);
Atezolizumab (genetical recombination) (JAN);
Tecentriq (TN)
Product
Formula
C6446H9902N1706O1998S42
Exact mass
144521.3941
Mol weight
144610.5555
Sequence
(Heavy chain)
EVQLVESGGG LVQPGGSLRL SCAASGFTFS DSWIHWVRQA PGKGLEWVAW ISPYGGSTYY
ADSVKGRFTI SADTSKNTAY LQMNSLRAED TAVYYCARRH WPGGFDYWGQ GTLVTVSSAS
TKGPSVFPLA PSSKSTSGGT AALGCLVKDY FPEPVTVSWN SGALTSGVHT FPAVLQSSGL
YSLSSVVTVP SSSLGTQTYI CNVNHKPSNT KVDKKVEPKS CDKTHTCPPC PAPELLGGPS
VFLFPPKPKD TLMISRTPEV TCVVVDVSHE DPEVKFNWYV DGVEVHNAKT KPREEQYAST
YRVVSVLTVL HQDWLNGKEY KCKVSNKALP APIEKTISKA KGQPREPQVY TLPPSREEMT
KNQVSLTCLV KGFYPSDIAV EWESNGQPEN NYKTTPPVLD SDGSFFLYSK LTVDKSRWQQ
GNVFSCSVMH EALHNHYTQK SLSLSPGK
(Light chain)
DIQMTQSPSS LSASVGDRVT ITCRASQDVS TAVAWYQQKP GKAPKLLIYS ASFLYSGVPS
RFSGSGSGTD FTLTISSLQP EDFATYYCQQ YLYHPATFGQ GTKVEIKRTV AAPSVFIFPP
SDEQLKSGTA SVVCLLNNFY PREAKVQWKV DNALQSGNSQ ESVTEQDSKD STYSLSSTLT
LSKADYEKHK VYACEVTHQG LSSPVTKSFN RGEC
(dimer; disulfide bridges: H22-H96, H145-H201, H221-L214, H227-H'227, H230-H'230, H262-H322, H368-H426, H'22-H'96, H'145-H'201, H'221-L'214, H'262-H'322, H'368-H'426, L23-L88, L134-L194, L'23-L'88, L'138-L'194)
  Type
Peptide
Remark
Therapeutic category: 4291
Product: D10773<JP/US>
Efficacy
Antineoplastic, Immune checkpoint inhibitor, Anti-PD-L1 antibody
  Disease
Urothelial carcinoma [DS:H00022]
Non-small cell lung cancer [DS:H00014]
Comment
Monoclonal antibody
Target
PDL1 (CD274) [HSA:29126] [KO:K06745]
  Pathway
hsa04514  Cell adhesion molecules (CAMs)
Brite
USP drug classification [BR:br08302]
 Antineoplastics
  Monoclonal Antibody/Antibody-Drug Conjugate
   Atezolizumab
    D10773  Atezolizumab (USAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
 4  Agents affecting cellular function
  42  Antineoplastics
   429  Miscellaneous
    4291  Other Antitumors
     D10773  Atezolizumab (USAN/INN); Atezolizumab (genetical recombination) (JAN)
Target-based classification of drugs [BR:br08310]
 Cell surface molecules and ligands
  Other cell surface molecules
   Immune checkpoints
    PDL1 (CD274)
     D10773  Atezolizumab (USAN/INN) <JP/US>
Antineoplastics [br08340.html]
 D10773
New drug approvals in the USA [br08319.html]
 New Molecular Entity and New Therapeutic Biological Product Approvals
  D10773
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D10773
New drug approvals in Japan [br08318.html]
 Drugs with new active ingredients
  D10773
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D10773
Pharmacogenomic biomarkers [br08341.html]
 Companion diagnostics
  D10773
BRITE hierarchy
Other DBs
CAS: 1380723-44-3
PubChem: 312642102
LinkDB All DBs

» Japanese version   » Back

DBGET integrated database retrieval system